Venture Capital Firms in the Netherlands

Curie Capital, founded in 2018 and headquartered in Amsterdam, Netherlands, is a venture capital firm specializing in early-stage investments within the life sciences sector. The firm focuses on Seed and Series A rounds, targeting innovative biotechnology, pharmaceutical, and medical technology companies, particularly those developing therapeutics, diagnostics, or class IIb and III medical devices.Curie Capital not only provides capital but also strategic support, leveraging its extensive network and experience to help build successful companies. Operating primarily from its current fund, Curie Capital 3, the firm complies with RVO seed capital regulations, investing exclusively in companies headquartered in the Netherlands that have not raised more than €3.5 million in equity or convertible loans.With the anticipated launch of Curie Capital 4 in 2025, the firm plans to broaden its investment scope to include high-impact life sciences companies across Europe, expanding beyond its Dutch-centric focus. The Curie Capital team consists of life science experts and business analysts who actively guide portfolio companies through research and development phases. The firm typically acts as a lead investor and syndicates investments with experienced co-investors.Notable portfolio companies include TargED Biopharmaceuticals, Citryll, and Avidicure, reflecting Curie Capital’s commitment to advancing cutting-edge medical innovations.

Curiosity VC is an early-stage venture capital firm that focuses on investing in AI-driven B2B software companies. The firm targets founders in the Nordic, Baltic, and Benelux regions who are building solutions designed to serve the world, rather than exploit it. Their investment strategy is centered around four key socio-economic themes: Sustainable Living (including PropTech, Energy, and ClimateTech), Trusted Society (covering LegalTech, Privacy, and Cybersecurity), Future of Work (encompassing Enterprise SaaS, HRTech, and DevOps), and Future of Commerce (such as Fintech, Marketing & Sales Automation, and Logistics).Founded in 2021 by experienced operator-investors Herman Kienhuis and Maurice Beckand Verwee, Curiosity VC brings over two decades of collective experience in the venture capital landscape. The firm operates with a community-powered approach, supported by an engaged network of entrepreneurs, expert advisors, and investors. They emphasize responsible AI development in Europe, fostering inclusive and diverse teams, and creating a co-ownership model where portfolio founders and advisors share in the fund's profits, with a portion reinvested into the entrepreneurial ecosystem through the Curiosity Foundation.Curiosity VC has built a diverse portfolio of software companies, with notable investments including Naq Cyber, Nimbles, Maxwell.ai, Polarsteps, Scoupy, NEO Finance, Litebit, Orq.ai, Deeploy, Strise, and BeCause. Their team has collectively invested in over 60 companies throughout their careers, serving as board members and advisors for pioneering technology startups. The firm typically invests in early-stage companies, specifically in Pre-Seed, Seed, Series A, and Series B funding rounds, with typical investments ranging from €100k to €1.5M.The core team at Curiosity VC includes Herman Kienhuis and Maurice Beckand Verwee as Founder & Managing Partners, Akshata Agarwal as Principal, Elliot Schouten as Investment Manager & CFO, Eva Formica as Investment Analyst, and Fleur as AI Analyst. This team is further bolstered by a strong advisory board comprising experts in HRtech, ESG, M&A law, marketing, cybersecurity, and product development, providing comprehensive support to their portfolio companies.

Forbion is a venture capital firm that specializes in the life sciences sector, with a particular focus on biotechnology and pharmaceuticals. Established in 2009, the firm has built a strong reputation for its investments in innovative life sciences companies. Forbion is dedicated to supporting the development of new therapeutics and technologies that can significantly impact healthcare outcomes.The firm operates primarily in Europe and North America, targeting regions that are known for their advancements in life sciences. Forbion's investment strategy emphasizes the importance of fostering innovation in healthcare, and it aims to partner with companies that are at the forefront of scientific research and development.With offices located in Amsterdam, Munich, and San Francisco, Forbion is well-positioned to leverage its extensive network and expertise in the life sciences industry. The firm is recognized for its commitment to nurturing the growth of its portfolio companies, providing not only financial support but also strategic guidance to help them navigate the complexities of the healthcare landscape.

FORWARD.one is a venture capital firm based in Amsterdam, focused on funding high-tech hardware and deeptech startups across Europe. Founded in 2017, the firm has carved out a niche in supporting early and growth-stage companies building transformative physical technologies. FORWARD.one’s portfolio includes startups developing advanced robotics, photonics, semiconductors, and sustainable industrial innovations, with a strong emphasis on solving complex engineering problems that have real-world applications.The firm provides more than capital—its team combines expertise in engineering, finance, and operations to actively support portfolio companies in scaling up. By maintaining a close, collaborative approach, FORWARD.one helps entrepreneurs navigate product development, manufacturing, and international expansion. This hands-on involvement is a hallmark of its value-add strategy and one of the reasons it's become a prominent backer in Europe’s hardware ecosystem.With over €200 million in assets under management, FORWARD.one continues to grow its investment platform and expand its presence across Europe. The firm is committed to advancing innovation in areas such as climate tech, automation, and next-generation manufacturing. Its headquarters are located in Amsterdam, with an expanding network of partnerships and co-investors throughout European tech hubs.

Gryphion is the single-family office of Rob Thielen, the founder and chairman of Waterland Private Equity, a major European investment firm. Based in Amsterdam, Netherlands, Gryphion serves as the private investment platform for the Thielen family, overseeing a portfolio that spans private equity, real estate, venture capital, and philanthropic interests. Gryphion was established to manage and preserve the wealth accumulated from Thielen’s career in private equity, particularly following the success of Waterland, which has grown into one of Europe’s most respected and high-performing private equity firms. With a strong background in mid-market buyouts and growth investments, Thielen brings a rigorous and strategic mindset to Gryphion’s capital allocation decisions. The office operates with a long-term investment horizon, seeking opportunities that combine stable returns with social and economic value creation. Gryphion’s portfolio includes direct investments in high-growth companies, co-investments alongside institutional funds, and diversified allocations across asset classes. It also maintains a presence in impact investing, with a focus on sustainability, education, and innovation. In addition to investment activities, Gryphion supports philanthropic endeavors aligned with the Thielen family's values. These include contributions to cultural institutions, academic research, and community development initiatives both in the Netherlands and internationally. Gryphion maintains a lean structure, relying on a small team of experienced professionals and strategic advisors. The family office emphasizes privacy and discretion, operating largely out of the public eye while maintaining strong governance and disciplined risk management practices. As a modern European family office, Gryphion reflects the blend of entrepreneurial success and responsible capital stewardship. It embodies the next phase of wealth management for one of Europe’s most successful private equity figures, with a focus on legacy, purpose, and long-term value.

Keen Venture Partners is a growth-stage venture capital firm based in Amsterdam, established in 2016. The firm specializes in backing high-potential technology companies across Europe, with a strong emphasis on strategic sectors such as cybersecurity, artificial intelligence, robotics, and space technologies. In 2025, the European Investment Fund (EIF) announced a €40 million investment into Keen's new European Defence and Security Tech Fund, marking a landmark EIF-backed initiative in this strategic area. Keen’s investment thesis revolves around identifying visionary founders and supporting them with capital, networks, and expertise to scale their innovations globally. Their multidisciplinary team operates with deep sector knowledge and has built a strong reputation across the European tech ecosystem.